JP2024504467A5 - - Google Patents

Info

Publication number
JP2024504467A5
JP2024504467A5 JP2023545955A JP2023545955A JP2024504467A5 JP 2024504467 A5 JP2024504467 A5 JP 2024504467A5 JP 2023545955 A JP2023545955 A JP 2023545955A JP 2023545955 A JP2023545955 A JP 2023545955A JP 2024504467 A5 JP2024504467 A5 JP 2024504467A5
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
nucleic acid
acid residue
represents amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504467A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/052282 external-priority patent/WO2022162233A2/en
Publication of JP2024504467A publication Critical patent/JP2024504467A/ja
Publication of JP2024504467A5 publication Critical patent/JP2024504467A5/ja
Pending legal-status Critical Current

Links

JP2023545955A 2021-02-01 2022-02-01 がん療法で使用するための乳酸脱水素酵素活性のポリペプチド阻害剤 Pending JP2024504467A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21154636.1 2021-02-01
EP21154636 2021-02-01
PCT/EP2022/052282 WO2022162233A2 (en) 2021-02-01 2022-02-01 Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy

Publications (2)

Publication Number Publication Date
JP2024504467A JP2024504467A (ja) 2024-01-31
JP2024504467A5 true JP2024504467A5 (cg-RX-API-DMAC7.html) 2025-02-13

Family

ID=74494850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545955A Pending JP2024504467A (ja) 2021-02-01 2022-02-01 がん療法で使用するための乳酸脱水素酵素活性のポリペプチド阻害剤

Country Status (6)

Country Link
US (1) US20240116987A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284920A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024504467A (cg-RX-API-DMAC7.html)
AU (1) AU2022214391A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206455A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022162233A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020221899A1 (en) * 2019-05-02 2020-11-05 Université Catholique de Louvain Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer
US12383216B2 (en) * 2023-06-23 2025-08-12 Smart Breast Corporation Stereotactic MBI-guided biopsy using a variable-angle slant-hole collimator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6444425B1 (en) * 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US20050130263A1 (en) * 1999-10-29 2005-06-16 Genesis Research And Development Corp. Ltd. Compositions isolated from bovine mammary gland and methods for their use
NZ704191A (en) 2010-06-14 2016-05-27 Hoffmann La Roche Cell-penetrating peptides and uses therof
WO2020221899A1 (en) * 2019-05-02 2020-11-05 Université Catholique de Louvain Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer

Similar Documents

Publication Publication Date Title
AU2007275860B2 (en) Modulators of pharmacokinetic properties of therapeutics
JP2024178382A5 (cg-RX-API-DMAC7.html)
JPWO2019156137A5 (cg-RX-API-DMAC7.html)
JP2026041749A5 (cg-RX-API-DMAC7.html)
JP2021534798A5 (cg-RX-API-DMAC7.html)
JP2010536714A5 (cg-RX-API-DMAC7.html)
JP2008536483A5 (cg-RX-API-DMAC7.html)
JP2024533312A5 (cg-RX-API-DMAC7.html)
JP2020530282A5 (cg-RX-API-DMAC7.html)
Wiener et al. The sequences of the reovirus serotype 1, 2, and 3 L1 genome segments and analysis of the mode of divergence of the reovirus serotypes
TW200904419A (en) Modulators of pharmacokinetic properties of therapeutics
JPWO2019107530A5 (cg-RX-API-DMAC7.html)
EA019965B1 (ru) Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
JP2021518159A5 (cg-RX-API-DMAC7.html)
JP2023538422A5 (cg-RX-API-DMAC7.html)
JP2016538885A5 (cg-RX-API-DMAC7.html)
JPWO2023026994A5 (cg-RX-API-DMAC7.html)
JP2024533315A5 (cg-RX-API-DMAC7.html)
JP2018515101A5 (cg-RX-API-DMAC7.html)
JP2019534884A5 (cg-RX-API-DMAC7.html)
JP2006506097A5 (cg-RX-API-DMAC7.html)
JP2024542995A5 (cg-RX-API-DMAC7.html)
JP2024511131A5 (cg-RX-API-DMAC7.html)
JP2022506716A5 (cg-RX-API-DMAC7.html)
TW201138773A (en) Dosage regimens for HCV combination therapy